Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2024 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

revolution medicines - RVMD

RVMD

Close Chg Chg %
60.60 -1.27 -2.10%

Closed Market

59.33

-1.27 (2.10%)

Volume: 1.24M

Last Updated:

Nov 12, 2024, 4:00 PM EDT

Trade Now

Company Overview: revolution medicines - RVMD

RVMD Key Data

Open

$60.04

 Day Range

58.63 - 60.82

52 Week Range

19.07 - 62.40

 Market Cap

$10.19B

Shares Outstanding

168.22M

 Public Float

141.22M

Beta

1.40

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$3.59

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

1.51M

  

RVMD Performance

1 Week
 
 -1.84%
 
1 Month
 
 17.53%
 
3 Months
 
 38.46%
 
1 Year
 
 201.01%
 
5 Years
 
 N/A
 

RVMD Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 15
Full Ratings ➔

About revolution medicines - RVMD

Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.

RVMD At a Glance

Revolution Medicines, Inc.
700 Saginaw Drive
Redwood City, California 94063
Phone 1-650-481-6801 Revenue 11.58M
Industry Pharmaceuticals: Other Net Income -436,367,000.00
Sector Health Technology Employees 378
Fiscal Year-end 12 / 2024
View SEC Filings

RVMD Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 280.236
Price to Book Ratio 2.586
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -3.097
Enterprise Value to Sales 127.818
Total Debt to Enterprise Value 0.059

RVMD Efficiency

Revenue/Employee 30,634.921
Income Per Employee -1,154,410.053
Receivables Turnover 9.234
Total Asset Turnover 0.008

RVMD Liquidity

Current Ratio 13.064
Quick Ratio 13.064
Cash Ratio 12.881

RVMD Profitability

Gross Margin 19.611
Operating Margin -4,207.124
Pretax Margin -3,798.713
Net Margin -3,768.282
Return on Assets -29.819
Return on Equity -34.751
Return on Total Capital -22.797
Return on Invested Capital -32.941

RVMD Capital Structure

Total Debt to Total Equity 4.816
Total Debt to Total Capital 4.594
Total Debt to Total Assets 4.211
Long-Term Debt to Equity 4.412
Long-Term Debt to Total Capital 4.209
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Revolution Medicines - RVMD

Collapse All in section
All values USD millions. 2020 2021 2022 2023 5-year trend
Sales/Revenue
42.98M 29.39M 35.38M 11.58M
Sales Growth
-14.10% -31.62% +20.38% -67.27%
Cost of Goods Sold (COGS) incl D&A
- 7.33M 9.66M 9.31M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
6.54M 7.33M 9.66M 9.31M
Depreciation
5.48M 6.26M 8.59M 8.24M
Amortization of Intangibles
1.07M 1.07M 1.07M 1.07M
COGS Growth
- - +31.70% -3.59%
-
Gross Income
- 22.06M 25.72M 2.27M
Gross Income Growth
- - +16.62% -91.17%
-
Gross Profit Margin
- +75.05% +72.71% +19.61%
2020 2021 2022 2023 5-year trend
SG&A Expense
147.13M 210.07M 284.00M 489.46M
Research & Development
128.57M 182.80M 248.03M 417.03M
Other SG&A
18.56M 27.27M 35.97M 72.42M
SGA Growth
+46.81% +42.77% +35.20% +72.34%
Other Operating Expense
- - - -
-
Unusual Expense
- - - (115.00K)
-
EBIT after Unusual Expense
(110.70M) (188.01M) (258.28M) (487.07M)
Non Operating Income/Expense
2.24M 929.00K 9.15M 47.18M
Non-Operating Interest Income
2.24M 929.00K 9.15M 47.48M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- - 71.00K 12.00K
-
Interest Expense Growth
- -33.02% -83.10% -100.00%
Gross Interest Expense
- - 71.00K 12.00K
-
Interest Capitalized
- - - -
-
Pretax Income
(108.53M) (187.09M) (249.13M) (439.89M)
Pretax Income Growth
-108.56% -72.39% -33.16% -76.57%
Pretax Margin
-252.50% -636.58% -704.14% -3,798.71%
Income Tax
- (371.00K) (420.00K) (3.52M)
Income Tax - Current - Domestic
- - (371.00K) 112.00K
-
Income Tax - Current - Foreign
- - - 212.00K
-
Income Tax - Deferred - Domestic
- - - (3.87M)
-
Income Tax - Deferred - Foreign
- - - 17.00K
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(108.16M) (187.09M) (248.71M) (436.37M)
Minority Interest Expense
- - - -
-
Net Income
(108.16M) (187.09M) (248.71M) (436.37M)
Net Income Growth
-126.92% -72.98% -32.93% -75.46%
Net Margin Growth
-251.63% -636.58% -702.95% -3,768.28%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(108.16M) (187.09M) (248.71M) (436.37M)
Preferred Dividends
- - - 2.22M
-
Net Income Available to Common
(110.38M) (187.09M) (248.71M) (436.37M)
EPS (Basic)
-1.6573 -2.5697 -3.0846 -3.8565
EPS (Basic) Growth
-57.96% -55.05% -20.04% -25.02%
Basic Shares Outstanding
66.60M 72.81M 80.63M 113.15M
EPS (Diluted)
-1.6573 -2.5697 -3.0846 -3.8565
EPS (Diluted) Growth
-57.96% -55.05% -20.04% -25.02%
Diluted Shares Outstanding
66.60M 72.81M 80.63M 113.15M
EBITDA
(104.15M) (180.68M) (248.62M) (477.88M)
EBITDA Growth
-107.55% -73.47% -37.61% -92.21%
EBITDA Margin
-242.31% -614.75% -702.72% -4,126.74%

Snapshot

Average Recommendation BUY Average Target Price 69.643
Number of Ratings 15 Current Quarters Estimate -1.009
FY Report Date 12 / 2024 Current Year's Estimate -3.492
Last Quarter’s Earnings -0.94 Median PE on CY Estimate N/A
Year Ago Earnings -3.86 Next Fiscal Year Estimate -4.055
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 15 10 16 16
Mean Estimate -1.01 -1.00 -3.49 -4.05
High Estimates -0.93 -0.74 -3.38 -3.25
Low Estimate -1.15 -1.12 -3.98 -4.65
Coefficient of Variance -5.69 -10.21 -4.06 -8.48

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 14 14 14
OVERWEIGHT 1 1 1
HOLD 0 0 1
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Insider Actions for Revolution Medicines - RVMD

Date Name Shares Transaction Value
Oct 4, 2024 Mark A. Goldsmith See Remarks; Director 302,192 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $44.8 per share 13,538,201.60
Oct 4, 2024 Mark A. Goldsmith See Remarks; Director 300,170 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $45.46 per share 13,645,728.20
Oct 4, 2024 Mark A. Goldsmith See Remarks; Director 310,170 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $4.09 per share 1,268,595.30
Oct 4, 2024 Mark A. Goldsmith See Remarks; Director 271,229 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jul 18, 2024 Stephen M. Kelsey See Remarks 272,952 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $47.02 per share 12,834,203.04
Jul 18, 2024 Stephen M. Kelsey See Remarks 276,752 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $46.08 per share 12,752,732.16
Jul 18, 2024 Stephen M. Kelsey See Remarks 282,512 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $44.94 per share 12,696,089.28
Jul 18, 2024 Stephen M. Kelsey See Remarks 284,640 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $43.99 per share 12,521,313.60
Jul 18, 2024 Stephen M. Kelsey See Remarks 285,740 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $4.09 per share 1,168,676.60
Jul 18, 2024 Stephen M. Kelsey See Remarks 73,332 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jul 18, 2024 Stephen M. Kelsey See Remarks 269,073 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $48.06 per share 12,931,648.38
Jul 17, 2024 Mark A. Goldsmith See Remarks; Director 291,229 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jul 17, 2024 Mark A. Goldsmith See Remarks; Director 25,424 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $45.01 per share 1,144,334.24
Jul 11, 2024 Sushil Patel Director 22,103 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $16.8 per share 371,330.40
Jul 11, 2024 Sushil Patel Director 32,490 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jul 11, 2024 Jeff Cislini General Counsel 47,088 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $40.83 per share 1,922,603.04
Jul 11, 2024 Sushil Patel Director 19,948 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $44 per share 877,712.00
Jun 25, 2024 Sandra J. Horning Director 95,287 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jun 25, 2024 Sandra J. Horning Director 16,700 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jun 25, 2024 Alexis A. Borisy Director 2,336,294 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Revolution Medicines in the News